U.S. Healthtech Stock News

Fidelis Insurance Holdings (NYSE:FIHL) has entered into a major share repurchase agreement that ends founding shareholder CVC Falcon Holdings Limited's ownership stake. The company has also approved amendments to its Bye Laws at its latest annual meeting, signaling changes to its governance framework. These decisions mark a meaningful shift in ownership and corporate rules that is relevant for existing and prospective shareholders. Fidelis Insurance Holdings, a specialty insurance and...

If you are wondering whether Incyte's current share price still offers value or has already priced in recent enthusiasm, the next sections will walk through what the numbers actually say. Over the past year the stock has returned 55.0%, with shorter term moves of 2.4% over 7 days, 2.8% over 30 days and a year to date return of a 4.4% decline, which can change how the market views both its growth potential and its risks. Recent coverage has focused on Incyte's position in biotech and the...

If you are wondering whether ASML Holding's current share price really reflects what you are getting, you are not alone. This article is designed to help you make sense of that question. ASML trades at US$1,427.02 after a 2.1% decline over the last 7 days, while the stock shows returns of 4.9% over 30 days, 22.6% year to date and 108.1% over the last year. These moves sit against a backdrop of ongoing interest in semiconductor equipment names, with investors closely watching how major...

TriMas (TRS) opened 2026 with Q1 revenue of $168.3 million and a basic EPS loss of $1.38, alongside earnings from discontinued operations of $852.6 million and net income from ongoing operations of $51.8 million. Over the past year, the company has seen trailing 12 month revenue move from $630.8 million to $661.5 million. Over the same period, basic EPS shifted from a small loss of $0.05 to a positive $0.47 as reported on a rolling basis. With net margin softening to 2.8% from 3.4% over the...

Huntsman (HUN) opened 2026 with Q1 revenue of US$1.4 billion and a basic EPS loss of US$0.30, while the trailing twelve months show revenue of US$5.7 billion and a basic EPS loss of US$1.87. Over recent quarters, revenue has ranged between US$1.4 billion and US$1.5 billion, with quarterly basic EPS losses stretching from roughly US$0.02 to US$0.92. Investors are therefore looking at a business that is still working through margin pressure rather than expanding profitability. See our full...

Wondering if Teradyne at US$345.42 is priced for perfection or still offers value? This article breaks down what the current market price might be implying. The stock has seen sharp moves, with a 17.4% decline over the last 7 days, an 11.6% gain over 30 days, and returns of 66.4% year to date and 356.9% over the past year. Recent coverage of Teradyne has focused on its role in semiconductors and automation, and how investor interest in these themes has lined up with the share price moves...

Why Comcast Stock Is Back in Focus Comcast (CMCSA) is drawing fresh attention after a stretch of mixed returns, with the share price at $27.19 and performance over the past month and past 3 months weighing on longer term holders. See our latest analysis for Comcast. At a share price of $27.19, Comcast’s recent 30 day share price return of a 2.65% decline and year to date share price return of a 7.96% decline sit alongside a 12.08% one year total shareholder return decline. This combination...

In late April 2026, Teva Pharmaceutical Industries reported first‑quarter 2026 results showing higher sales of US$3,982 million and net income of US$369 million, alongside much smaller impairment charges than a year earlier. Beyond the headline numbers, growth in innovative products such as UZEDY and the planned acquisition of Emalex Biosciences signal a deeper shift toward higher‑margin neuroscience and specialty medicines. Now we will examine how Teva’s stronger first‑quarter profitability...

Nutex Health (NUTX) is back on investors’ radar after Q1 2026 results showed net income more than doubling year over year, stronger EPS, and continued hospital expansion plans supported by its existing arbitration driven model. See our latest analysis for Nutex Health. That earnings surprise and expansion pipeline have coincided with a sharp rebound in the shares, with a 1 day share price return of 17.1%, 7 day share price return of 28.9% and 30 day share price return of 41.8%. The 1 year...

Greg Abel is set to lead his first Berkshire Hathaway (NYSE:BRK.B) annual meeting as CEO following Warren Buffett's retirement. The meeting places Abel at the center of investor attention as shareholders assess the leadership transition. Investors are watching how Abel addresses concerns around performance, capital allocation, and Berkshire's long term direction. Berkshire Hathaway class B shares last closed at $473.01, with a return of 62.6% over 5 years and 46.0% over 3 years. Over the...

Wondering if Alphabet's share price actually lines up with its underlying value, or if enthusiasm has run ahead of the numbers. Alphabet recently closed at US$385.69, with reported returns of 12.0% over 7 days, 29.7% over 30 days, 22.4% year to date and 135.9% over 1 year. Recent headlines have focused on Alphabet's role in artificial intelligence and ongoing product updates across search, cloud services and advertising. These stories help explain why investors are paying close attention to...

MaxLinear (NasdaqGS:MXL) introduced its Washington 200G per lane optical transimpedance amplifier for 1.6T AI data center interconnects. Samples of the new TIA are currently available to customers, with mass production targeted for the second half of 2026. The launch comes as the company reports upgraded sales targets and momentum in its optical business. For investors tracking AI infrastructure, this move places MaxLinear closer to the core of next generation data center build outs. The...

Coca-Cola (KO) is back in focus for investors after recent trading data highlighted steady share price moves over the past week, month, and past 3 months, inviting a closer look at its current valuation. See our latest analysis for Coca-Cola. Those recent weekly and monthly share price gains sit within a stronger backdrop, with a 13.69% year to date share price return and a 67.32% total shareholder return over five years, pointing to momentum that investors are reassessing against Coca-Cola’s...

Kearny Financial Corp. ( NASDAQ:KRNY ) stock is about to trade ex-dividend in 3 days. Typically, the ex-dividend date...

Addus HomeCare Corporation ( NASDAQ:ADUS ), is not the largest company out there, but it received a lot of attention...

Some Texas Instruments Incorporated ( NASDAQ:TXN ) shareholders may be a little concerned to see that the Independent...

A week ago, Glaukos Corporation ( NYSE:GKOS ) came out with a strong set of first-quarter numbers that could...

BorgWarner Inc. recently announced it will pay a quarterly dividend of US$0.1700 per share on June 15, 2026, and disclosed new eMotor contracts with Asian automakers for electric and hybrid vehicle programs in South Korea and China. These awards expand BorgWarner’s electrification footprint in key Asian markets by supplying stator assemblies and advanced winding technologies for next-generation hybrid and battery electric platforms. Next, we’ll examine how these new Asian eMotor program...

This article examines whether Okta, trading at around US$75.78, may be attractively priced or could instead represent a value trap, and explores what the current price might be implying about the business. The stock has had a mixed performance, with a 0.3% decline over the past 7 days, a 4.3% drop over the last 30 days, a 9.4% fall year to date, and a 32.9% decline over the past year, while the 3-year return stands at 2.7% and the 5-year return at a 68.1% loss. Recent headlines have...

Tecnoglass (TGLS) has drawn investor attention after a stretch of weaker share performance, with the stock showing a 42% decline over the past year despite revenue of US$983.61m and net income of US$159.57m. See our latest analysis for Tecnoglass. At the current share price of US$42.57, Tecnoglass has seen pressure build over recent months, with a 30 day share price return of 5.38% and a 1 year total shareholder return of 42.17%, suggesting momentum has been fading rather than building. If...

Wondering whether FactSet Research Systems at around US$227.58 still reflects its true worth, or if the market has moved ahead of the fundamentals. The stock has risen 1.5% over the last 7 days and 1.2% over the last 30 days, although year to date it is down 20.1% and the 1 year return sits at a 46.9% loss. These moves come as investors reassess established financial data and analytics providers. FactSet Research Systems is often mentioned in discussions around long term demand for market...

Hims & Hers Health (HIMS) is back in focus as Amazon’s One Medical pushes further into weight management, while fresh data security lawsuits and upcoming FDA weight loss discussions add legal and regulatory questions. See our latest analysis for Hims & Hers Health. The recent pullback, including a 10.31% 7 day share price return and earlier single day drops related to Amazon’s expansion and data breach lawsuits, sits alongside a 38.16% 30 day share price return and a 153.80% 5 year total...

Western Digital (WDC) has put up another big quarter, with Q2 2026 revenue at US$3.0b and basic EPS of US$5.27, backed by trailing twelve month revenue of US$10.7b and EPS of US$11.40 that reflect a very large year over year earnings swing. Over recent quarters, the company has seen revenue move from US$2.2b in Q1 2025 to US$3.0b in Q2 2026, while basic EPS has shifted from US$0.43 to US$5.27. This sets up a story where higher reported profitability, supported by a 36.8% trailing net margin...

The Gross Law Firm recently announced a class action lawsuit on behalf of Oddity Tech shareholders, alleging the company made materially false and misleading statements about digital advertising costs after an algorithm change by its largest advertising partner increased customer acquisition costs and hurt its business outlook. This legal challenge raises fresh questions about how dependent Oddity’s business model is on a single digital ad ecosystem and the transparency of its cost...